You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Progression to trastuzumab and taxanes.

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer Trial in Shanghai (Pertuzumab)

Not yet recruiting
  • Breast Cancer
  • Shanghai, Shanghai, China
    Shanghai Jiaotong University School of Medicine affiliated Ruiji
Jun 4, 2023

Her 2 Positive Breast Cancer, Breast Cancer Female, Breast Cancer Metastatic Trial in Boston (Sacituzumab Govitecan,

Not yet recruiting
  • Her 2 Positive Breast Cancer
  • +2 more
  • Sacituzumab Govitecan
  • +2 more
  • Boston, Massachusetts
  • +1 more
Oct 25, 2023

HER2-positive Breast Cancer Trial (Tucatinib (Combination of tucatinib-Oral VP16-trastuzumab))

Not yet recruiting
  • HER2-positive Breast Cancer
  • Tucatinib (Combination of tucatinib-Oral VP16-trastuzumab)
  • (no location specified)
Jul 20, 2023

Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast, Advanced Breast Cancer Trial (Trastuzumab,

Recruiting
  • Brain Metastases
  • +2 more
  • Saint Louis, Missouri
  • +1 more
Nov 8, 2022

Advanced Breast Cancer, Objective Response Rate, Trastuzumab Emtansine Trial in Nanjing (Trastuzumab Emtansine (T-DM1))

Recruiting
  • Advanced Breast Cancer
  • +2 more
  • Trastuzumab Emtansine (T-DM1)
  • Nanjing, Jiangsu, China
    JiangSu Province Hospital/ The First Affiliated Hospital of Nanj
Nov 5, 2023

Breast Cancer Trial in Strasbourg (Microbiopsy sample, Muscle echography, Maximal strength, Body composition, Quality of life

Completed
  • Breast Cancer
  • Microbiopsy sample
  • Muscle echography, Maximal strength, Body composition, Quality of life and Physical activity level
  • Strasbourg, France
    Institut de Cancerologie Strasbourg Europe
Jun 7, 2021

Metastatic Breast Cancer With a Isolated Brain Progression Trial in France (Tucatinib, Pertuzumab, Trastuzumab)

Recruiting
  • Metastatic Breast Cancer With a Isolated Brain Progression
  • Angers, France
  • +33 more
Aug 10, 2022

HER2-positive Breast Cancer, Brain Metastases Trial in Beijing, Guangzhou, Hangzhou (Trastuzumab, Taxanes, Pertuzumab)

Not yet recruiting
  • HER2-positive Breast Cancer
  • Brain Metastases
  • Beijing, Beijing, China
  • +2 more
May 28, 2021

HER2-positive Breast Cancer, Metastatic Breast Cancer Trial in Shanghai (Trastuzumab plus chemo, Trastuzumab in combination with

Recruiting
  • HER2-positive Breast Cancer
  • Metastatic Breast Cancer
  • Trastuzumab plus chemotherapy
  • Trastuzumab in combination with pyrotinib plus chemotherapy
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Apr 20, 2022

Metastatic Breast Cancer Trial in United States (Pertuzumab, Trastuzumab)

Completed
Has Results
  • Metastatic Breast Cancer
  • Tucson, Arizona
  • +15 more
Dec 3, 2021

Trastuzumab(Henlius®) Combined With Pertuzumab(Perjeta®) and

Recruiting
  • HER2-positive Metastatic Breast Cancer
  • +2 more
  • trastuzumab(Henlius®) combined with Pertuzumab(Perjeta®) and Chemotherapy
  • Beijing, Beijing, China
    Ruyan Zhang
Dec 27, 2021

Breast Cancer Trial in Paris, Barcelone, Madrid (Trastuzumab and non-pegylated liposomal doxorubicin)

Completed
Has Results
  • Breast Cancer
  • Trastuzumab and non-pegylated liposomal doxorubicin
  • Paris, France
  • +3 more
Feb 8, 2022

HER2-mutant NSCLC Trial in China (Trastuzumab deruxtecan)

Recruiting
  • HER2-mutant Non-Small Cell Lung Cancer
  • Trastuzumab deruxtecan
  • Baoding, China
  • +29 more
Jul 20, 2022

Addition of Docetaxel to Standard Treatment in First-line

Completed
  • HER2-positive Gastric Cancer
  • +3 more
  • Besançon, Franche-Comté, France
    CHU Besancon
Jun 4, 2021

HER2-positive Recurrent/Metastatic Breast Cancer Trial (Inetetamab, pyrotinib, chemo)

Not yet recruiting
  • HER2-positive Recurrent/Metastatic Breast Cancer
  • Inetetamab, pyrotinib, chemotherapy
  • (no location specified)
Nov 16, 2022

Breast Cancer Trial in Nanjing (Inetetamab, Pyrotinib, Oral Vinorelbine Tartrate)

Recruiting
  • Breast Cancer
  • Nanjing, Jiangsu, China
    The First Affiliated Hospital with Nanjing Medical University
Apr 10, 2023

Breast Cancer, Pyrotinib, Breast Diseases Trial in Guangzhou (Pyrotinib 320mg + Vinorelbine, Pyrotinib 400mg + Vinorelbine,

Recruiting
  • Breast Cancer
  • +4 more
  • Pyrotinib 320mg + Vinorelbine
  • +2 more
  • Guangzhou, China
    Zhang Jingmin
Apr 24, 2022

pCR After Neoadjuvant Therapy in Breast Cancer Patients

Recruiting
  • Breast Cancer
  • TIL assessment in pre-existing histopathological specimens
  • Cairo, Egypt
    Faculty of Medicine, Ain Shams University
Jul 25, 2022

Inetetamab Combined With Pyrotinib and Vinorelbine as First-line

Recruiting
  • Breast Neoplasms
  • Nanjing, Jiangsu, China
    Jiangsu Provincial People's Hospital
Mar 16, 2023

Breast Cancer Trial (Pyrotinib, Epirubicin, Cyclophosphamide)

Not yet recruiting
  • Breast Cancer
  • (no location specified)
Feb 27, 2020

Adenocarcinoma Trial in Chicago (Trastuzumab, ABT-806, Bemarituzumab)

Completed
Has Results
  • Adenocarcinoma
  • Chicago, Illinois
    University of Chicago
Mar 15, 2021

Metastatic Breast Cancer Trial in Worldwide (Trastuzumab, Pertuzumab, Paclitaxel)

Completed
  • Metastatic Breast Cancer
  • Amiens, France
  • +70 more
Mar 29, 2021

Metastatic Breast Cancer Trial in Worldwide ((vic-)trastuzumab duocarmazine, Physician's choice)

Active, not recruiting
  • Metastatic Breast Cancer
  • (vic-)trastuzumab duocarmazine
  • Physician's choice
  • Mobile, Alabama
  • +89 more
Oct 20, 2022

Malignant Solid Tumor Trial in Philadelphia (Biopsy, Biospecimen Collection, Echocardiography)

Active, not recruiting
  • Malignant Solid Neoplasm
  • Biopsy
  • +5 more
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
Nov 15, 2023

Breast Cancer Trial in Beijing (Inetetamab, Rapamycin, Pyrotinib)

Not yet recruiting
  • Breast Cancer
  • Beijing, China
    National Cancer Center/National Clinical Research Center for Can
Jan 31, 2021